GLP-1 and Dual Agonists May Significantly Reduce New Sleep Apnea Cases

Obstructive Sleep Apnea (OSA) is a common and serious condition linked to obesity, metabolic syndrome, and increased cardiovascular risk. While GLP-1 receptor agonists and dual GLP-1/GIP agonists are highly effective for weight loss and glycemic control, their impact on the development of new sleep apnea cases in a real-world setting has been less clear. This study addresses whether these powerful metabolic drugs can prevent the incidence of new physician-reported sleep apnea diagnoses.

The study revealed a significant reduction in the incidence of new sleep apnea diagnoses among patients treated with GLP-1 and dual agonists. Patients receiving GLP-1 receptor agonists showed a 30% lower risk (p<0.001) of developing new sleep apnea compared to the control group. The effect was even more pronounced with dual GLP-1/GIP agonists, which were associated with a 45% reduction (p<0.0001) in new diagnoses. This translates to an incidence rate of 5.2 cases per 1000 patient-years in the control group, compared to 3.6 cases in the GLP-1 group and 2.8 cases in the dual agonist group. The most impactful finding was that dual GLP-1/GIP agonists nearly halved the incidence of new sleep apnea diagnoses, demonstrating a substantial protective effect beyond their known metabolic benefits.